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Abstract
There are a great variety of human membrane proteins, which currently form the largest group of
marketed drug targets. However, despite the advances in drug design, promiscuity between drug
molecules and targets often leads to undesired signaling effects, which result in side effects from
treatment. In this review, one family of membrane proteins – G protein-coupled receptors
(GPCRs) – is used as a model to review experimental techniques that may be used to examine the
activity of membrane proteins. As these receptors are highly relevant to healthy human physiology
and represent the largest family of drug targets, they represent an excellent model for membrane
proteins in general. We also review experimental evidence that suggests there may be multiple
ways to target a GPCR – and by extension, membrane proteins – to more effectively target
unhealthy phenotypes while reducing the occurrence and severity of side effects.
1. Membrane proteins as therapeutic targets
Membrane proteins reside at intracellular interfaces and serve in a wide variety of critical
cellular functions, including signal relay, cell structure, binding, and transport of molecules
across otherwise impermeable membranes. Given the critical roles these proteins play in
human physiology, it is of little surprise that a plurality of drugs currently on the market
attenuates disease phenotypes through membrane proteins. In a study of the DrugBank [1,
2], it was found that 44% of all drugs patented since 1982 primarily target receptors. Our
own examination, linking the DrugBank and SIDER databases [3], finds roughly 526
distinct membrane-localized targets that are known to interact with a drug, summarized in
Table 1.
For any particular protein, there may be many more known ligands than successfully
marketed drugs. One well-described subfamily of membrane proteins, the adenosine
receptors – belonging to the superfamily of G protein-coupled receptors (GPCRs) – is
known to interact with 12 marketed drugs [2], yet is the target of 88 known natural and
synthetic ligands [4]. This receptor subfamily alone has been proposed as targets in
treatments for ischemia, neurodegenerative disorders, cancer, and diabetes [5], among other
conditions. The “recognition promiscuity” of drugs with the adenosine receptors, and the
GPCR family generally, frequently leads to unintended physiological responses – i.e. side
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effects, as shown in Table 1. These effects present an ongoing challenge to researchers,
clinicians, and patients, but also represent an opportunity to improve future generations of
drugs.
As indicated in Table 1, there appears to be great potential for improving the specificity of
therapeutics in the future, thus reducing the occurrence of adverse effects. Given the
complexity and diversity of membrane protein families, a comprehensive review of the
various types of membrane proteins and their therapeutic potential is beyond the scope of
this review. Here, we will focus on current techniques that may be used to improve the
effectiveness of future drugs, using studies with GPCRs as a model. We will highlight these
techniques while describing advances in understanding typical orthosteric ligand binding, as
well as other modes of signal modulation that have received more attention in recent years,
such as allosteric ligand binding, protein-protein interactions, and protein-membrane
interactions. These various mechanisms of signal modulation are illustrated in Figure 1. The
experimental techniques to isolate and identify these signaling effects are well known, but
must be combined usefully to better inform drug design (Figure 2), both for efficacy and to
reduce the occurrence and severity of adverse effects.
2 Molecular mechanisms of GPCR signaling: Enhancing therapeutic design
through structure-function studies
The canonical means of modulating molecular signaling is through orthosteric effects of a
receptor, either by direct ligand-binding interaction, or by restricting access to the ligand-
binding region of the receptor. This is the mechanism by which most signal modulation is
achieved [6]. However, in recent years a number of alternative mechanisms have been
observed in a few membrane proteins, which may have a broad applicability to membrane
protein drug targeting.
Allosteric ligands act away from the traditionally recognized binding site [7], and thus do
not necessarily affect ligand binding at the orthosteric site. Ligands could modulate the
pharmacological response to treatment by combining the effects of ortho- and allosteric
binding, thus fine-tuning the effects of treatment using each signaling mechanism. This type
of approach also could potentially take advantage of differential expression profiles [8] of a
membrane protein among tissues to further alleviate side effects of a drug. The synergistic
effects of ortho- and allosteric ligands with varied receptor levels among tissues are not well
understood, but could prove to be a valuable tool in future [9].
Protein-protein interactions have been found to modulate receptor signaling as well [10].
However, the proteins involved in these interactions may themselves be further modified,
e.g. through phosphorylation [11]. Some of these interactions are known in vivo (e.g. RGS
(Regulator of G protein Signaling) proteins [11]); thus there is potential to modulate
signaling through a route other than direct ligand binding [12], perhaps in ways that are not
normally present in the native system.
The lipid environment of the plasma membrane also provides an interface that has been
postulated to modify receptor activity [13, 14]. Cells derived from different tissue naturally
have differing lipid compositions [15], and separate domains of lipid composition have been
observed within single cells as well [16]. Lipid interacting domains have been speculated to
exist in receptors [17], and specific lipid-receptor interactions may further modulate receptor
signaling [18]. All of these methods of signal modulation may exist simultaneously in vivo,
as in Figure 1. Using these methods singly or in conjunction to develop novel therapies for
disease may help minimize the risks of side effects through greater specificity.
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3 Research methods for structure-function analysis of GPCRs
3.1 Animal models
Signaling effects of a receptor are most naturally gauged by observing phenotypic effects of
modulation in the native environment. Studies of this type have been performed in a number
of multicellular organisms, particularly in Drosophila melanogaster and Mus musculus.
These experiments have been highly illuminating, as knockout studies have revealed critical
signaling pathways required for successful embryonic development [19], cardiological
protective effects [20], and a variety of neuropathic phenotypes among other results [21].
Ledent et al. [22] demonstrated that the knockout of adenosine A2A receptor led to a mouse
phenotype exhibiting increased basal anxiety and aggressiveness, and decreased stimulation
by caffeine. The protein-receptor interaction mouse model study reported by Ichikawa-
Shindo et al. [23] examined adrenomedullin/receptor activity modifying protein 2 (AM/
RAMP2) and showed non-lethal effects resulted from partial knockout; RAMP2+/− models
showed increased vascular hyperpermeability and increased blood pressure. The full
knockout model (RAMP2−/−) did not survive through embryogenesis, indicating how
important the presence of the receptor interaction was for the development of the animal
[23].
An even more fundamental pathway was found in studies in fruit fly models [24]. The
prototypical frizzled-type GPCR pathway was identified using this model; the frizzled
family of receptor has since been found to play an outsized role in everything from
embryogenesis through neurological development [25]. These studies demonstrated the
breadth of importance of the GPCRs and associated proteins in support of healthy,
functional phenotypes in the animals. However, development of these models requires
substantial resources and time, rendering these techniques intractable for refining the
molecular details of receptor signaling.
3.2 Cell culture models
Cell culture has been an invaluable vehicle for the engineering of receptors. The relatively
high turnaround and ease of experimentation has led to a number of advances in the
understanding of receptor activity in vivo [26, 27]. There are numerous means of examining
the behavior of receptors in the cellular environment, several of which are highlighted here.
Lead experiments typically involve cloning the cDNA of the receptor into an appropriate
vector that is then expressed in a cell line of interest [28, 29]. This type of overexpression
allows the examination of trafficking, regulation, and signaling behavior of a single receptor
type in the cellular environment. For example, in studies addressing GPCRs of the nervous
system, the γ-aminobutyric acid (GABA) receptors bind to inhibitory ligand GABA and to
the excitatory ligand glutamate, and proved to be complicated to study in the native system.
Thus, this receptor was cloned in the early 90s, and subsequently found to be active as a
dimer of the GABAB1 and GABAB2 subunits [30-33]. The availability and expression of a
cloned receptor enabled the development of high-throughput drug discovery and lead
compound identification, including those that enabled the development of cinacalcet for
hypercalcemia [34], and LY487379 and other potential compounds for schizophrenia [35].
Pitfalls have been encountered using this technique, however. GPCRs, and generally
membrane proteins, are often poorly expressed in heterologous hosts, greatly limiting the
proteins available for study using heterologous expression. Substantial resources have been
devoted solely to the expression of these receptors in heterologous hosts over the years, and
a number of studies have collected and reviewed expression data from many hosts as a
means of improving the expression of receptors in general [28, 29, 36]. Heterologous host
systems frequently do not have a proteome similar to the native tissue a researcher is seeking
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to emulate. Observation of the native-like behavior of the receptor may require more than
expression; interacting species may not be present in the heterologous system, and may be
required to develop a complete picture of the signaling activity of the receptor. In spite of
these potential limitations, a number of experimental techniques taking advantage of
heterologous expression have been used to examine in vivo effects of receptor signaling.
The discovery, characterization, and subsequent cloning of fluorescent proteins have
allowed receptor tagging for observing trafficking and signaling activity in the cellular
environment [37]. Using simple tagging by genetic engineering methods has enabled the
examination of receptor fate within the cell. This basic method has been expanded to take
advantage of advanced microscopy techniques [38, 39] and facilitated a more intricate
understanding of receptor behavior in the cell. Total internal reflection fluorescence (TIRF)
microscopy [40] and fluorescent photoactivation localization microscopy (FPALM) [41]
have been used to examine the specific localization of tagged receptors within the plasma
membrane. TIRF, fluorescence correlation spectroscopy (FCS) [42], and fluorescence
lifetime imaging microscopy (FLIM) [43] have also been used to examine colocalization
through particle tracking or overlapping fluorescence signals.
The latter techniques have also been used to examine the oligomerization state of receptors
in cells. Many recent studies have found that receptors expressed at the plasma membrane
frequently form dimers, trimers, or higher order oligomers [40, 44, 45]. In GPCRs, evidence
has been found that this type of mechanism operates in some, though not all, receptors [46].
The degree to which this interaction influences signaling remains an open question.
To demonstrate oligomerization, the Förster resonance energy transfer (FRET) effect is
frequently used in conjunction with bioluminescent or fluorescent proteins, as described in
[47, 48]. Briefly, the excited fluorophore or reacting substrate resonantly donates energy to a
separate fluorophore, which emits a photon characteristic of the acceptor emission spectrum,
rather than the donor. This emission may be monitored by any fluorimetric method; transfer
occurs when the donor and acceptor are within a range of roughly 1-10 nm, thus giving
strong evidence of colocalization. This basic technique has been refined to further examine
the proximity of each fluorophore, partial fluorophore, or luciferase fusion to the other
markers present in the cells. In particular, bimolecular fluorescence complementation
(BiFC) [49] and luciferase complementation imaging (LCI) [50] have been engineered to
allow additional, persistent protein-protein interactions to be detected. Three-chromophore
FRET has also been experimentally demonstrated [51], further expanding the degree of the
interaction network that may be examined simultaneously.
However, given the nature of the experiment and the limited area of the membrane, it is
difficult to establish the significance of these interactions. It may be challenging to eliminate
the possibility of false positives in the measurements, particularly as the number of tagged
proteins in the complex increases. Additionally, receptors are often overexpressed in
engineered cell lines to collect this type of data. With many fewer receptors at the plasma
membrane in native tissue, the burden of proof remains on the researcher to confirm the
physiological relevance of oligomerization in native tissue [52]. The presence of confirmed
inter-receptor interactions could introduce a novel therapeutic path for treatment; thus
continued research into the interaction phenomenon is important.
Downstream signaling data may be used to experimentally determine the activation state of
receptor-mediated pathways. A variety of methods to examine this activation have been
developed. For example, commercially available kits based on intracellular Ca2+ or cAMP
(cyclic adenosine monophosphate) accumulation are available to monitor downstream
signaling activity resulting from GPCR activation, providing high throughput signaling
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assays. These techniques require the chemical treatment of cells to obtain signaling data and
thus may be time-intensive, but have been applied successfully with mammalian systems
[53]. Additionally, endogenous downstream pathway activation in Saccharomyces
cerevisiae may be linked to an observable signal; β-galactosidase activity [54], growth [55],
or fluorescence-based [56] signaling assays have been used with live cells. Fluorescence and
growth-based assays of this type, in particular, have improved the overall throughput of
examining signaling activity in cells. As with any system, there are caveats to monitoring
signaling activity in mammalian, insect, or fungal systems. Generally, insect or mammalian
cells are capable of folding and expressing the receptor, but not successfully in all cases, and
are expensive and time consuming to use [36]. Conversely, in lower eukaryotic systems, the
receptors may express poorly and concerns remain over appropriate signal relay in the
heterologous host.
Genetic mutation has also been used to examine receptor-signaling mechanisms. Directed
and random mutagenesis studies have been used to identify residues of the receptor that are
critical for ligand-binding activity, downstream signaling, or successful trafficking through
the secretory pathway [57, 58]. Once a heterologous host organism has been identified, it is
also possible to use scanning mutagenesis to identify thermostabilizing mutations for further
study [59]. As described in Section 3.3, this technique has been used to identify stabilized
forms of a given receptor for structural analysis [60], as well as for studying signal dynamics
and to elucidate structural insight from biophysical characterization [61]. Mutagenic
methods have thus become an invaluable tool for probing the structures of receptors in the
cellular environment, as well as a tool for in vitro analysis.
3.3 Purification and structural analysis
Heterologous expression of GPCRs has pressed forward over the years as the most
straightforward alternative to models in native tissues or animals, and remains the most
frequent means of obtaining large quantities of protein for further characterization in vitro.
Only rhodopsin has been crystallized from its native tissue with its intact sequence; all other
GPCRs have required protein engineering to stabilize the receptor or facilitate crystallization
[62]. Protein engineering and expression have been performed using a variety of model cell
systems, including bacteria, yeast, insect, and mammalian cell lines [28, 63, 64]. Expression
in all of these systems has yielded mixed results, leading to the continued use of trial and
error approaches to determine the best expression system for any particular receptor [29].
When an adequate expression system is identified, these cell lines produce sufficient protein
sample for further study using powerful in vitro methods.
Following expression, purification of membrane proteins from culture has been the major
bottleneck preventing further characterization [63]. Structural crystallography and other
biophysical studies require solubilization and purification from the cellular debris.
Detergents must be tested for the solubilization and structural stabilization of the membrane
protein [65, 66]. Detergent interaction could compromise the protein activity through direct
interactions, or due to physical properties of micelles, as micelle dimensions are expandable
and have a high degree of curvature [67]. These characteristics may not appropriately mimic
the membrane environment and can pose challenges for crystal contact formation [61, 68].
The end goal of this lengthy process is to obtain a highly purified receptor that retains its
native structure, dynamics and ligand-binding functionality in order to properly model in
vivo signaling activity [67].
Historically, high-resolution structures have been the ideal paradigm for understanding the
mechanism of protein interactions and how the structure relates to the biological function of
membrane proteins. Most drug discovery projects against soluble protein targets have used
medicinal chemistry, directed or guided by the crystal structures, at some stage of the project
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[69]. Structure-based drug discovery methods have not been widely applied to GPCRs, and
membrane proteins in general, due at least partially to the lack of crystal structures. There
have been more challenges to structural resolution of membrane proteins than originally
anticipated, in part due to the low expression level of membrane proteins in their native
tissue [70], the instability of receptors in detergent solutions, and structural or
conformational flexibility [67] of the purified protein. As of August 2012, there were 83,983
protein structures in the RCSB Protein Data Bank. Of these, less than 3% of the structures
were of membrane-associated proteins and peptides [15, 71], corresponding to 355 unique
membrane proteins (data obtained from Stephen White’s website, http://
blanco.biomol.uci.edu/mpstruc/listAll/list). Thus, structural knowledge for membrane
proteins remains far underrepresented compared to that of soluble proteins [72].
However, the rate of the structural determination of membrane proteins has increased in the
past twelve years, and there are now high-resolution crystal structures for fourteen different
GPCRs, as part of the 355 aforementioned structures. For a recent review on high-resolution
GPCR crystal structures, refer to [73]; since this review, the structures of four more GPCRs
have been determined: Sphingosine 1-phosphate receptor, M2 and M3 human muscarinic
acetylcholine receptors, κ-opioid receptor, μ-opioid receptor, δ-opioid receptor, and
nociceptin/orphanin FQ receptor [74-79]. Some of these structures were determined with a
variety of bound ligands (both agonist and antagonist), lipids, or the intracellular G protein
[62, 80, 81]. These crystal structures revealed common and diverse features of the GPCRs,
important characteristics of the ligand-binding pocket, GPCR motifs, possible allosteric
sites, dimerization interfaces and structural conformational changes in the receptor important
for G protein interaction [73, 80]. These structures, together with continuing advances in
expression and crystallization of membrane proteins, will open the possibility to use
structure-based methods for the identification and design of new pharmaceuticals targeted to
these membrane proteins [69, 80].
The structural knowledge gained from these experiments has opened valuable insights into
the activity of receptors while introducing new questions, as the complexity of the signaling
pathway has become clearer. The emergence of new types of ligand-receptor-effector
relationships [62], and the understanding of how lipids and oligomerization state modulate
signaling have provided evidence for signaling mechanisms away from the orthosteric
ligand binding site that may provide rich targets for therapeutics [73]. Many of these
questions may be answered with more high-resolution crystal structures of membrane
proteins, specifically capturing transitional structures as the receptor enters an active
signaling state [82]; or through structural data of the receptors in native-like environments
[67]. However, the mechanisms behind receptor signaling may also be elucidated by
building upon structural information, with complementary dynamic observation
methodologies.
3.4 Establishing a native-like environment in membrane-mimetics
Once the receptor is purified using detergents it may be reconstituted in lipids or other
detergents to further stabilize the receptor. The choice of molecule for solubilizing and
reconstituting the receptor is critical for the biophysical measurements to be taken, as
different methods will leave the receptor in micelles, bicelles, liposomes, or in supported
bilayers [83]. The geometry and composition of the membrane environment is critical not
only for the characterization technique being used, but also for the membrane protein itself.
There is growing evidence of the importance of the membrane environment for the
modulation of membrane protein function [80]. Differential receptor activity has been
reported in tissues or membranes with different lipid composition [80, 84], though in these
cases it remains unclear whether the interaction is directed through specific lipid-protein
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interactions or due to differences in the physical characteristics of the membrane (e.g.
curvature, fluidity, and thickness) [80, 85].
Recent experiments have found that reconstitution of at least one receptor (β2-adrenergic
receptor) in lipid bilayers or micelles that mimic native conditions better recovers the native
signaling properties of the receptor [86]. Purified adenosine receptor A2A loses its ligand
binding activity when reconstituted in detergent, but when reconstituted in detergent with a
cholesterol analogue, the receptor retains native ligand-binding affinity. When this micellar
system was characterized using small-angle neutron scattering, the addition of cholesterol
changed the micelle size (ellipsoidal with a thickness of 32 Å), and so better reflected the
thickness of mammalian membranes [87]. Thus, it remains unclear whether the cholesterol
is essential for signaling due to direct binding to the protein or due to the changes in the
micellar environment.
3.5 Observing dynamic interactions of membrane proteins
By monitoring the dynamic response of the receptor during an experiment, a deeper
understanding of the structural motions involved in signaling may be achieved. Subtle
interactions among lipids, membrane proteins and the effector molecules sharing the
membrane environment with the GPCR may be captured. Many techniques have been used
to collect dynamic data regarding various regions within the receptor, and have the
advantage that the receptor may be stabilized in native-like environments following
purification and its function can be tested using biologically relevant conditions.
One of the most fundamental types of studies is to investigate binding of extracellular ligand
to receptor. When designing experiments to investigate the receptor ligand-binding
interaction, it is important to consider the desired ligand characteristics in order to choose
the appropriate technique to capture these interactions. For small molecules, fluorescent [88,
89] or radiolabeled [52] ligands may be available and the ligand binding can be tested using
purified or reconstituted receptors, membrane preparations, or whole cells [90, 91]. When
labeled ligands are not available, downstream monitoring methods may be used, as
discussed in Section 3.2 and in [91]. Additionally, surface plasmon resonance (SPR)
methods have been used to examine the binding of receptor to known, though unlabeled,
ligand [90, 92, 93]. Beyond observing ligand-binding behavior in well-established cases,
there are orphan receptors – those with no known ligands – and there is much literature
dedicated to classifying and de-orphaning these receptors [94, 95].
The changes in receptor conformation associated with ligand binding may be monitored by
observing the intrinsic tryptophan fluorescence. A receptor with a tryptophan residue that is
close to the binding pocket or in an area that undergoes a conformational change upon
ligand-binding experiences a change in the local hydrophobicity of the environment; in turn,
this may be quantitatively determined by changes in fluorescence intensity. When coupled
with static structural data and the location of tryptophan in the protein, the dynamics of the
receptor may be captured as the receptor changes conformation, e.g. upon addition of
ligands. Many groups have used this technique to calculate the dissociation constant or to
ensure that the purified receptor retains ligand-binding activity [96]. Environmentally
sensitive probes and intrinsic fluorescence have also been used to monitor the interaction
between receptors and G proteins; fluorescence was measured and conformational changes
and binding rates were observed with various ligands and detergent and lipid compositions
[97-99].
This principle has been extended to examine receptors using probes other than tryptophan,
which are likewise sensitive to the local environment. Both Fourier transform infrared
(FTIR) and nuclear magnetic resonance (NMR) studies have taken advantage of these
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effects to inspect the subtle conformational changes of the receptor during ligand-binding
events, and have shown the ability to discriminate between the changes in signaling pathway
activation using different agonists. For example, a particularly detailed and careful study of
rhodopsin using FTIR combined with p-azido-L-phenylalanine probes enabled the analysis
of electrostatic interactions during conformational transitions in rhodopsin [100]. Another
study principally using NMR was able to determine mechanistic behavior of ligand
signaling sensitivity in the β2-adrenergic receptor [101]. Using local probes in these
manners yields powerful insights into the conformational consequences of signaling activity,
and so potentially identifies a means through which to modulate cellular activity with new
drug designs.
The changes in receptor conformation associated with the membrane environment may also
be traced with the methods mentioned above. It is also possible to study specific protein-
lipid properties, such as the lipid binding site, protein affinity for lipids, lipid localization
and interaction dynamics [102]. In particular, as the resolution of GPCR structures increases,
specific lipid contacts may be identified. For example, one of the latest GPCR structures
(PDB 4EIY) was determined at 1.8 Å resolution; 57 water, 2 cholesterol, and 23 lipid
molecules were identified with the receptor [103].
Possible signal modulation by lipids has been observed in vitro using nanodiscs, where the
addition of negatively charged lipids did not affect ligand binding activity; however, the
lipid charge had a strong influence on the GPCR-G protein interaction [104]. Understanding
the role of lipids in the function of membrane proteins will reveal important details about
receptor segregation, trafficking, activation, and downstream signaling. Once we understand
the lipid-receptor interactions we may be able to target the lipids of the membrane itself for
therapy. For example, in native tissue, toxins may generate their effects via interactions with
the membrane itself, thereby impairing the function of multiple membrane proteins [85].
Creating therapeutics to target a cell surface could thus be an effective option, in principle.
Furthermore, drug-targeting strategies may be designed to take advantage of specific
membrane compositions, or to introduce novel interaction with receptors at the cell surface.
The principle of such mechanisms has been demonstrated by engineering the surface of
therapeutic cells or the membranes of target cells by coupling immune-inhibitory ligands or
small molecules, expressing artificial receptors or insertion of polymers, peptides and
proteins [105]. Drug design taking advantage of these mechanisms has the potential to
redefine cell adhesion, migration, tissue homing, and cell-cell interaction [105].
3.6 Computational modeling
Over the last decade, advances in computer hardware and algorithm design have made
molecular dynamic (MD) simulation much more tractable [106, 107]. All-atom MD
simulations can allow the characterization of the motions of ligand-bound or ligand-free
states, as well as interaction of the protein with the membrane environment (e.g. GPCR
signaling with lipid dynamics has been modeled [108]). Multi-scale simulations, ranging
from full atomistic to coarse-grained models, have been used to study membrane
components at various levels of complexity, giving a balance between enough detail to
describe the features of interest and limited computer power [83]. As more structural data
becomes available, and the cost of computational power falls, MD should provide
increasingly cost- and time-effective insight into signaling behavior.
Similarly to MD, docking simulations based on homology modeling have been performed as
more crystal structures become available [109, 110]. One recent example of this approach
utilized the crystal structure of β2-adrenergic receptor to screen one million compounds,
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followed by experimental testing of twenty-five compounds, yielding six active compounds,
of which one obtained an affinity of 9 nM, suggesting great promise for this approach [111].
Another example involves the histamine receptor family: H1 has been the target of
antihistamine drugs and H4 is being investigated as the target for drugs to treat asthma and
itching. H1 antihistamine efficacy might be improved if H4 is targeted in conjunction, in
order to reduce further itching and inflammation [112]. Using a structure-based virtual
fragment screening protocol, de Graaf et al. [113] identified two fragments that could
potentially target the H1 and H4 receptors. Taken together, these advances argue for the
rational development of dual H1-H4 ligands with synergistic anti-allergenic, anti-itching,
and anti-inflammatory properties. Though these studies are less rigorous than MD
simulation, they are less computationally intensive and provide for higher drug screening
throughput. Thus docking studies may provide a useful aid in future studies, in addition to
MD [114].
4 Novel biopharmaceuticals targeting GPCR interfaces
As this review has shown, a plethora of analytical techniques has been used to determine the
key components of receptor signaling, both in vivo and in vitro. The complexity of these
signaling systems is exceptional, however, and using the correct tools to precisely determine
the mechanism of signaling within tissue at the cellular level remains challenging. The basic
mechanism – ligand binding, conformational change, and intracellular relay – through which
receptors affect cell signaling are well understood, and yet this protein family is still yielding
surprises today. As more is learned about the nuances of signaling, there will be more
opportunities for improving the specificity of therapeutics, refining the effects of
pharmaceuticals and perhaps alleviating unwanted side effects. As the interfacial phenomena
of membrane proteins become better understood, the applicability of drugs targeting these
regions of the receptors will only grow.
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Schematic of the membrane environment and GPCR signaling. (I) Single receptor molecules
are generally capable of transducing a signal to the intracellular medium. Several regions of
the receptor may modulate this signal. The most common means is modulation by
orthosteric ligand binding, which is caused by the binding of agonists or antagonists (site a).
Allosteric ligand binding sites may allow either soluble species (site b) or membrane-soluble
species, including lipids, to access the receptor (site c). (II) Protein-protein interactions, here
between two receptor molecules, a receptor and a heterotrimeric G protein, and a receptor
activity modulating protein (RAMP). These inter-protein interactions may also modulate
signaling behavior upon ligand binding to the receptor. As with all proteins in the cellular
milieu, these are subject to regulatory proteins, which further modulate the overall signaling
potential of receptors at the cell surface. There is also therapeutic potential in designing
molecules, peptide or otherwise, that modulate signaling analogously to RAMP-like species.
(III) The membrane itself has intrinsic mechanical properties the receptor must
accommodate, in addition to specific interactions. These properties may shift the
conformation of the receptor toward or away from active conformation.
McNeely et al. Page 16














Development of human therapeutics is by necessity built upon many experimental
foundations. GPCR interactions with other proteins, ligands, or the cell membrane are best
identified in isolation and then combined to form a holistic snapshot of receptor behavior.
Animal models (manuscript section §3.1) show how tissues, or whole organisms, may react
to treatment, but require substantial resources and studies are typically directed by results
from cell cultures (§3.2). Therapeutic effects may be even more intensively examined
through structural analysis (§3.3), as well as biophysical studies of protein in isolation in
liposomes, micelles, or other biomimetic systems (§3.4-3.5). Finally, molecular dynamics
and docking studies (§3.6) are used to study the movements of individual receptors. The
collection of data from all of these experiments is required for the development of drugs that
more specifically treat a condition, while minimizing the risk of adverse effects.
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Table 1
The number of unique approved drugs that target various classes of membrane-localized proteins, as well as
the total number of side effects resulting from those drugs. It may be possible to reduce the burden of a disease
while also reducing side effects by better targeting of the protein and tissue affected by a disease. The method
to obtain data is described in the Supporting Information and a complete listing of targets, target type, drugs,
and side effects is given in the Table S1 of the Supporting Information.
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